Why $NAUT it's zero to one: biology can already read DNA cheaply ($ILMN) but still can't read proteins at scale, and proteins are what actually run the body and what nearly every drug targets. Today's tools, mass spectrometry and antibody panels, miss most low abundance proteins and can't tell apart the many versions of the same protein (called proteoforms). Remember the word because it will be very important in the future. PROTEOFORMS. Nautilus puts single protein molecules on a chip with billions of spots and reads each one through hundreds of cycles of probes. In theory that measures most of the proteome, and every proteoform, one molecule at a time. Nobody else does it this way, which is why it's a new capability rather than a better version of an existing one. The generational part: Patel took Isilon from a garage to a $2.25B sale to EMC, and he's rebuilt that team plus Illumina/Solexa veterans around Mallick, an Aebersold trained protein scientist who has spent his whole career on this problem. They have years of patents behind them, and insiders keep buying near the lows. If broadscale works, the company could matter as much for proteins as Illumina did for DNA, and from roughly a 260M market cap that would be a 50-100x+ outcome. That's the real bull case. The product isn't on the market yet. Today it's a paid service for one assay (Tau). The instrument (Voyager) opens for pre orders in early 2027 and ships around mid 2027. The big, proteome wide assay which would be the holy grail of biotech is not ready its performance tests in Q2 and has no launch date at the moment so they turn their focus into a platform they can monitize today while they work on the impossible but I have very high confidence that they have the people to deliver. They have never raised cash post IPO but they will eventully need to in 2027 to commercialize. Cash: about $129M in total Burn is around $27M every 6 months, so the runway is roughly 2+ years. The market value sits barely above cash, which is why it feels like a Series A price. The things to watch are a new broadscale timeline, the AKT1 assay in late 2026, and how many Voyager pre-orders come in early 2027

if you actually want to make money in the hardest market in the world, listen to me. i've tracked all the bio "gurus and experts" on X, they dont understand markets and generational companies. I do. $NAUT yes, dont but any other biotech stock, there is no point.